Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s product is a drug-device combination consisting of molgramostim nebulizer solution (drug component) and a vibrating mesh nebulizer (device component). Molgramostim nebulizer solution is vialed as a sterile formulation containing molgramostim solution. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system for administration of molgramostim nebulizer solution. The eFlow® consists of a controller unit, a nebulizer handset, and a connection cord. The SVRA average annual return since 2017 is shown above.
The Average Annual Return on the SVRA average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SVRA average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SVRA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|